{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:49Z","timestamp":1789186129188,"version":"build-2803163510"},"reference-count":36,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1253\/circrep.cr-26-0156","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:10:32Z","timestamp":1784326232000},"page":"1431-1441","source":"Crossref","is-referenced-by-count":0,"title":["One-Month Outcomes of Aspirin-Free Strategy for Percutaneous Coronary Intervention With or Without Proton-Pump Inhibitors\u3000\u2015 A Post Hoc Subgroup Analysis of STOPDAPT-3 \u2015"],"prefix":"10.1253","volume":"8","author":[{"given":"Ryota","family":"Nishio","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Data Science, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Wakayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ogita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Domei","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Isawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sendai Kousei Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dokkyo Medical University Saitama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Hisauchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dokkyo Medical University Saitama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tokuyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kawaguchi Cardiovascular and Respiratory Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shizuoka General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Wakayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Nanasato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Okayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ehime Prefectural Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Juntendo University Shizuoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the STOPDAPT-3 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing 3 antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med<\/i> 1998; 339: 1665\u20131671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. <i>Circulation<\/i> 2024; 149: 585\u2013600.","DOI":"10.1161\/CIRCULATIONAHA.123.066720"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. <i>Eur Heart J<\/i> 2023; 44: 3720\u20133826.","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC\/AHA\/SCAI Guideline for coronary artery revascularization: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2022; 79: 197\u2013215.","DOI":"10.1016\/j.jacc.2021.09.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. <i>N Engl J Med<\/i> 2010; 363: 1909\u20131917.","DOI":"10.1056\/NEJMoa1007964"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Casado Arroyo R, Polo-Tomas M, Roncal\u00e9s MP Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy. <i>Heart<\/i> 2012; 98: 718\u2013723.","DOI":"10.1136\/heartjnl-2012-301632"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Marzot F, Pengo V. Prasugrel for the treatment of patients with acute coronary syndrome. <i>Vasc Health Risk Manag<\/i> 2009; 5: 321\u2013324.","DOI":"10.2147\/VHRM.S3428"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2007; 357: 2001\u20132015.","DOI":"10.1056\/NEJMoa0706482"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wiviott SD, Trenk D, Frelinger AL, O\u2019Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. <i>Circulation<\/i> 2007; 116: 2923\u20132932.","DOI":"10.1161\/CIRCULATIONAHA.107.740324"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kuno T, Miyamoto Y, Akita K, Shoji S, Numasawa Y, Ueda I, et al. Low-dose prasugrel vs. standard-dose clinicalopidogrel for patients undergoing percutaneous coronary intervention. <i>Circ J<\/i> 2024; 88: 1778\u20131787.","DOI":"10.1253\/circj.CJ-24-0173"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. O\u2019Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of 2 randomised trials. <i>Lancet<\/i> 2009; 374: 989\u2013997.","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. <i>JAMA<\/i> 2019; 321: 2414\u20132427.","DOI":"10.1001\/jama.2019.8145"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. <i>Lancet<\/i> 2018; 392: 940\u2013949.","DOI":"10.1016\/S0140-6736(18)31858-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial. <i>JAMA<\/i> 2020; 323: 2407\u20132416.","DOI":"10.1001\/jama.2020.7580"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishida M, Shimada R, Takahashi F, Niiyama M, Ishisone T, Matsumoto Y, et al. One-month dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after biodegradable polymer drug-eluting stent implantation: The REIWA region-wide registry. <i>Circ J<\/i> 2024; 88: 876\u2013884.","DOI":"10.1253\/circj.CJ-24-0091"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kogame N, Nakagawa Y, Kozuma K, Iijima R, Tsutsui A, Murakami Y, et al. Sex-based differences in the effect of short dual antiplatelet therapy followed by prasugrel monotherapy in high-bleeding-risk patients after percutaneous coronary intervention. <i>Circ Rep<\/i> 2026; 8: 554\u2013563.","DOI":"10.1253\/circrep.CR-25-0298"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Natsuaki M, Morimoto T, Shiomi H, Kadota K, Tada T, Takeji Y, et al. Effects of acute coronary syndrome and stable coronary artery disease on bleeding and ischemic risk after percutaneous coronary intervention. <i>Circ J<\/i> 2021; 85: 1928\u20131941.","DOI":"10.1253\/circj.CJ-21-0016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Numao Y, Takahashi S, Nakao YM, Tajima E, Noma S, Endo A, et al. Sex differences in bleeding risk associated with antithrombotic therapy following percutaneous coronary intervention. <i>Circ Rep<\/i> 2024; 6: 99\u2013109.","DOI":"10.1253\/circrep.CR-24-0015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kobayashi N, Shibata Y, Kurihara O, Todoroki T, Tsutsumi M, Shirakabe A, et al. clinical background and coronary artery lesions characteristics in Japanese patients with acute coronary syndrome suffering major bleeding. <i>Circ Rep<\/i> 2024; 6: 64\u201373.","DOI":"10.1253\/circrep.CR-24-0003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. <i>Circulation<\/i> 2019; 140: 240\u2013261.","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. <i>Circulation<\/i> 2011; 123: 2736\u20132747.","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. <i>Circulation<\/i> 2007; 115: 2344\u20132351.","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase III, randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2009; 374: 119\u2013125.","DOI":"10.1016\/S0140-6736(09)61246-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. <i>N Engl J Med<\/i> 2005; 352: 287\u2013289.","DOI":"10.1056\/NEJMe048330"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamamoto K, Yamamoto E, Morimoto T, Shiomi H, Domei T, Taniguchi R, et al. Long-term effects of proton pump inhibitors in patients undergoing percutaneous coronary intervention in high-risk subgroups. <i>Circ J<\/i> 2024; 88: 1778\u20131787.","DOI":"10.1253\/circj.CJ-24-0371"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Weisz G, Smilowitz NR, Kirtane AJ, Rinaldi MJ, Parvataneni R, Xu K, et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: The ADAPT-DES study. <i>Circ Cardiovasc Interv<\/i> 2015; 8: e001952.","DOI":"10.1161\/CIRCINTERVENTIONS.114.001952"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, Torp-Pedersen C, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. <i>Eur Heart J<\/i> 2019; 40: 1963\u20131970.","DOI":"10.1093\/eurheartj\/ehz104"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Liu YH, Cao ZY, Dai YN, Zeng LH, Zhang YS, Fan HL, et al. Association of proton pump inhibitor and infection and major adverse clinical events in patients with ST-elevation myocardial infarction: A propensity score matching analysis. <i>Front Med (Lausanne)<\/i> 2022; 9: 882341.","DOI":"10.3389\/fmed.2022.882341"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial. <i>JAMA Cardiol<\/i> 2022; 7: 407\u2013417.","DOI":"10.1001\/jamacardio.2021.5244"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. <i>J Am Coll Cardiol<\/i> 2008; 51: 256\u2013260.","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. <i>JAMA<\/i> 2009; 301: 937\u2013944.","DOI":"10.1001\/jama.2009.261"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shuldiner AR, O\u2019Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. <i>JAMA<\/i> 2009; 302: 849\u2013857.","DOI":"10.1001\/jama.2009.1232"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. <i>N Engl J Med<\/i> 2009; 360: 354\u2013362.","DOI":"10.1056\/NEJMoa0809171"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Padhi BK, Khatib MN, Zahiruddin QS, Rustagi S, Sharma RK, Sah R, et al. Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: A systematic review and meta-analysis. <i>BMC Cardiovasc Disord<\/i> 2024; 24: 372.","DOI":"10.1186\/s12872-024-04029-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis. <i>Front Pharmacol<\/i> 2021; 12: 694698.","DOI":"10.3389\/fphar.2021.694698"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. <i>J Clin Pharmacol<\/i> 2008; 48: 475\u2013484.","DOI":"10.1177\/0091270008315310"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-26-0156\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:25:51Z","timestamp":1789183551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-26-0156\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0156","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"CR-26-0156"}}